642 related articles for article (PubMed ID: 23136927)
1. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions.
Barbaud A; Collet E; Milpied B; Assier H; Staumont D; Avenel-Audran M; Grange A; Amarger S; Girardin P; Guinnepain MT; Truchetet F; Lasek A; Waton J;
Br J Dermatol; 2013 Mar; 168(3):555-62. PubMed ID: 23136927
[TBL] [Abstract][Full Text] [Related]
2. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.
Choon SE; Lai NM
Indian J Dermatol Venereol Leprol; 2012; 78(6):734-9. PubMed ID: 23075643
[TBL] [Abstract][Full Text] [Related]
3. Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations.
Teraki Y; Shibuya M; Izaki S
Clin Exp Dermatol; 2010 Oct; 35(7):723-8. PubMed ID: 19874350
[TBL] [Abstract][Full Text] [Related]
4. [Surveillance of severe cutaneous drug reactions: experience REACT-Lombardia].
Gamba C; Schroeder J; Citterio A; Cazzaniga S; Rivolta AL; Vighi G;
Recenti Prog Med; 2014 Oct; 105(10):379-84. PubMed ID: 25282350
[TBL] [Abstract][Full Text] [Related]
5. Severe cutaneous adverse reactions related to systemic antibiotics.
Lin YF; Yang CH; Sindy H; Lin JY; Rosaline Hui CY; Tsai YC; Wu TS; Huang CT; Kao KC; Hu HC; Chiu CH; Hung SI; Chung WH
Clin Infect Dis; 2014 May; 58(10):1377-85. PubMed ID: 24599767
[TBL] [Abstract][Full Text] [Related]
6. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.
Wolkenstein P; Chosidow O; Fléchet ML; Robbiola O; Paul M; Dumé L; Revuz J; Roujeau JC
Contact Dermatitis; 1996 Oct; 35(4):234-6. PubMed ID: 8957644
[TBL] [Abstract][Full Text] [Related]
7. Clinical features and prognostic factors in severe cutaneous drug reactions.
Yang MS; Kang MG; Jung JW; Song WJ; Kang HR; Cho SH; Min KU
Int Arch Allergy Immunol; 2013; 162(4):346-54. PubMed ID: 24193402
[TBL] [Abstract][Full Text] [Related]
8. Severe cutaneous adverse reactions: A 5-year retrospective study at Hospital Melaka, Malaysia, from December 2014 to February 2020.
Tee CT; Abdullah NH; Kristummoonthy P; Lee CS
Med J Malaysia; 2022 Jul; 77(4):409-414. PubMed ID: 35902928
[TBL] [Abstract][Full Text] [Related]
9. Acute generalized exanthematous pustulosis: analysis of cases managed in a tertiary hospital in Singapore.
Lee HY; Chou D; Pang SM; Thirumoorthy T
Int J Dermatol; 2010 May; 49(5):507-12. PubMed ID: 20534083
[TBL] [Abstract][Full Text] [Related]
10. Aetiopathogenesis of severe cutaneous adverse reactions (SCARs) in children: A 9-year experience in a tertiary care paediatric hospital setting.
Liccioli G; Mori F; Parronchi P; Capone M; Fili L; Barni S; Sarti L; Giovannini M; Resti M; Novembre EM
Clin Exp Allergy; 2020 Jan; 50(1):61-73. PubMed ID: 31608511
[TBL] [Abstract][Full Text] [Related]
11. A 10-years retrospective study on Severe Cutaneous Adverse Reactions (SCARs) in a tertiary hospital in Penang, Malaysia.
Loo CH; Tan WC; Khor YH; Chan LC
Med J Malaysia; 2018 Apr; 73(2):73-77. PubMed ID: 29703869
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.
Ding WY; Lee CK; Choon SE
Int J Dermatol; 2010 Jul; 49(7):834-41. PubMed ID: 20618508
[TBL] [Abstract][Full Text] [Related]
13. Phenytoin-associated hypersensitivity syndrome with features of DRESS and TEN/SJS.
Viera MH; Perez OA; Patel JK; Jones I; Berman B
Cutis; 2010 Jun; 85(6):312-7. PubMed ID: 20666193
[TBL] [Abstract][Full Text] [Related]
14. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking.
Walsh SA; Creamer D
Clin Exp Dermatol; 2011 Jan; 36(1):6-11. PubMed ID: 21143513
[TBL] [Abstract][Full Text] [Related]
15. Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non-case analysis using the Food and Drug Administration Adverse Event Reporting System.
Godfrey H; Jedlowski P; Thiede R
Australas J Dermatol; 2024 May; 65(3):243-253. PubMed ID: 38572842
[TBL] [Abstract][Full Text] [Related]
16. A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions.
Lin YT; Chang YC; Hui RC; Yang CH; Ho HC; Hung SI; Chung WH
J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):356-64. PubMed ID: 22211830
[TBL] [Abstract][Full Text] [Related]
17. Clinical features and prognostic factors of severe cutaneous adverse drug reactions: A single-center retrospective study of 209 cases in China.
Deng M; Su Y; Wu R; Li S; Tang G; Kuang Q; Luo X; Zhu Y; Shen W
Int Immunopharmacol; 2023 Jan; 114():109530. PubMed ID: 36508915
[TBL] [Abstract][Full Text] [Related]
18. Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.
Mustafa SS; Ostrov D; Yerly D
Curr Allergy Asthma Rep; 2018 Mar; 18(4):26. PubMed ID: 29574562
[TBL] [Abstract][Full Text] [Related]
19. Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS).
Ogawa K; Morito H; Hasegawa A; Daikoku N; Miyagawa F; Okazaki A; Fukumoto T; Kobayashi N; Kasai T; Watanabe H; Sueki H; Iijima M; Tohyama M; Hashimoto K; Asada H
J Dermatol Sci; 2013 Jan; 69(1):38-43. PubMed ID: 23141052
[TBL] [Abstract][Full Text] [Related]
20. Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs).
Torres-Navarro I; de Unamuno-Bustos B; Botella-Estrada R
J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):607-614. PubMed ID: 32846030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]